# Specific Biologics Raises $35M for ALS Gene Editing

> Specific Biologics secures $35M Series A to advance ALS gene editing into human trials.
- Title: Specific Biologics Raises $35M for ALS Gene Editing · Dealroom
- Summary: Specific Biologics secures $35M Series A to advance ALS gene editing into human trials. Specific Biologics raised $35 million for its ALS gene-editing…
- Keywords: specific biologics, als, gene editing, series a, clinical trials, toronto, hatteras venture partners, lumira ventures, admare bioinnovations, genesys capital, business development bank of canada, deepwork capital
- Source: Dealroom — https://dealroom.co/news/168917-specific-biologics-raises-35m-series-a-to-take-als-gene-editing-into-the
- Published: 2026-11-02T15:56:53+00:00
- Read time: 1 min
- Topics: specific biologics, als, gene editing, series a, clinical trials, toronto, hatteras venture partners, lumira ventures, admare bioinnovations, genesys capital, business development bank of canada, deepwork capital
## Series A Funding
Specific Biologics closed an oversubscribed US$35 million Series A to advance its lead gene-editing candidate toward human trials.
## Investors
Hatteras Venture Partners led the round, joined by Lumira Ventures and adMare BioInnovations.
## Endgame
The company develops precision gene-editing therapies for serious genetic diseases using its Dualase platform.
## Key takeaway

Specific Biologics raised $35 million for its ALS gene-editing therapy to enter clinical trials.